MANCHESTER, U.K., and HYDERABAD, India — Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions have announced an Integrated CMC Partnership aimed at providing innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services.
The collaboration brings together Sai Life Sciences’ API development expertise, Agility Life Sciences’ formulation capabilities, and Centrix Pharma Solutions’ strengths in drug product development and clinical manufacturing. The partnership is designed to streamline the path from preclinical studies to first-in-human (FIH) clinical trials, offering a single point of contact and integrated project management across all stages.
Unified Expertise and Seamless Execution
By combining deep expertise across the CMC value chain, the Integrated CMC Partnership helps customers create and execute holistic development plans—translating molecular hits into new medicines. Key benefits include:
- Broad scientific expertise across multiple disciplines, supported by extensive laboratory and manufacturing facilities
- End-to-end service coverage from synthetic route scouting to drug substance manufacturing, and from pre-formulation through to clinical trial material manufacturing
- Cross-functional optimization: integrated planning across API and drug product development, reducing duplication, risks, costs, and timelines
- Agility and flexibility to respond proactively to emerging technical risks across functions
- Seamless coordination between technical teams, including proactive sample transfer and early API evaluation in the drug product process
- Single point of contact from Day One, ensuring alignment and accountability throughout project execution
Partner Perspectives
“By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency,” said Krishna Kanumuri, MD & CEO, Sai Life Sciences.
“Our combined expertise and energy will enable our clients’ molecules to be accelerated through key milestones, while reducing risk and cost,” added Dr. Claire Thompson, CEO and Founder, Agility Life Sciences.
“This partnership creates a seamless environment where expertise flows freely, challenges are solved collectively, and clients benefit from true alignment,” said Chris Davison, CEO, Centrix Pharma Solutions.
Together, the three organizations state that the initiative will help innovators move molecules from discovery to the clinic more quickly, turning promising science into medicines that can change lives.
